Related Experiment Video
Updated: Aug 2, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Present treatment options for atrial fibrillation
S K S Lairikyengbam1, M H Anderson, A G Davies
1Bronglais General Hospital, Aberystwyth, Swansea. slairik@hotmail.com
Postgraduate Medical Journal
|March 4, 2003
Summary
Atrial fibrillation (AF) is a common heart rhythm disorder significantly increasing stroke risk. This review explores effective rhythm control strategies and novel non-pharmacological treatments for managing AF.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia.
- AF contributes to over 35% of US hospital admissions for cardiac arrhythmias.
- It doubles population mortality and significantly elevates stroke risk, particularly in older adults.
Purpose of the Study:
- To discuss optimal rhythm control strategies for atrial fibrillation.
- To explore the rhythm versus rate control debate.
- To highlight advances in non-pharmacological AF treatments.
Main Methods:
- Review of current literature on atrial fibrillation management.
- Discussion of pharmacological and non-pharmacological treatment approaches.
- Analysis of rhythm control versus rate control strategies.
Main Results:
- Diagnosis of AF is typically straightforward, but effective treatment remains challenging.
- Maintenance of sinus rhythm post-cardioversion requires antiarrhythmic drugs.
- Thromboembolism prevention is a critical aspect of AF management.
Conclusions:
- Effective rhythm control is key to managing atrial fibrillation.
- Non-pharmacological approaches offer promising new avenues for AF treatment.
- A comprehensive strategy addressing rhythm, rate, and thromboembolism is essential for optimal AF patient outcomes.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:26Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
01:25Dysrhythmias VI: Management of Dysrhythmias
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:25ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...